Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

Pages

13 results
6:10 PM, Feb 13, 2017  |  BioCentury | Emerging Company Profile

Divide or conquer

a 2011 deal with Epizyme Inc. to discover, develop and commercialize small molecules that target histone methyltransferases
12:00 AM, Jul 25, 2016  |  BioCentury | Finance

Leverage over genes

on a single aspect, such as super-enhancers, long non-coding RNA or chromatin-modifying proteins such as histone methyltransferases
12:00 AM, Mar 21, 2016  |  BioCentury | Emerging Company Profile

Targeting toxicity

anticancer activity without the toxicity issues associated with ETPs. ETPs are fungal metabolites that inhibit histone methyltransferases
12:00 AM, Aug 05, 2013  |  BioCentury | Strategy

Future-proofing MM

In 2012, Celgene partnered with Epizyme Inc. to discover and develop cancer therapeutics that inhibit histone methyltransferases
12:00 AM, Apr 30, 2012  |  BioCentury | Finance

Highlights of weekly biotech stock moves

Separately, Celgene partnered with Epizyme Inc. to discover, develop and commercialize cancer therapeutics that inhibit histone methyltransferases
12:00 AM, Jan 23, 2012  |  BioCentury | Strategy

Epigenetics land grab

to reconstitute anything like EZH2 activity. And you would have to do that with all histone methyltransferases
NV subsidiary to discover inhibitors of two undisclosed cancer targets. Epizyme has focused only on histone methyltransferases
just EZH2 or when we need to study the whole PRC2 complex." Gould noted that histone methyltransferases
12:00 AM, Jan 23, 2012  |  BioCentury | Emerging Company Profile

RaNA: Specific in epigenetics

Most epigenetics companies aim to globally inhibit regulatory proteins, such as histone methyltransferases or histone demethylases, which …
12:00 AM, Jun 27, 2011  |  BioCentury | Emerging Company Profile

EpiTherapeutics: Built BRIC by BRIC

EpiTherapeutics ApS is one of at least three companies founded since 2007 to work on histone methyltransferases
targets with approved drugs: histone deacetylases (HDACs) and DNA methyltransferases. According to CEO Martin Bonde, histone methyltransferases
For example, there are only 11 known specific HDAC subtypes, but there are 96 known histone methyltransferases
12:00 AM, Mar 28, 2011  |  BioCentury | Product Development

Epigenetic edge

linked to lymphoma, while GSK is collaborating with Epizyme to target an undisclosed set of histone methyltransferases
12:00 AM, Feb 21, 2011  |  BioCentury | Strategy

Sweet Spot revisited

going after novel spaces. Epizyme is tackling cancer via a family of epigenetic enzymes called histone methyltransferases

Pages